Frauger et al., Fundamental & clinical pharmacology, 2011
- Titre traduit : Mise en évidence du détournement d’usage du clonazépam : résultats des outils développés par le réseau français des CEIP
- Auteurs : E. Frauger, V. Pauly, V. Pradel, F. Rouby, J. Arditti, X. Thirion, M. Lapeyre Mestre, J. Micallef
- Résumé : Recent observations suggest the existence of clonazepam abuse. To determine its importance in France, a quantitative and systematic synthesis of all clonazepam data of several epidemiological tools of the Centers for Evaluation and Information on Pharmacodependence (CEIP) network has been performed in comparison with data on others benzodiazepines (BZD). Data on clonazepam and other BZD have been analysed from different epidemiological tools: OSIAP survey that identiﬁes drugs obtained by means of falsiﬁed prescriptions, Observation of Illegal Drugs and Misuse of Psychotropic Medications (OPPIDUM) survey that describes modalities of use and data from regional French health reimbursement system. In OSIAP survey, the proportion of clonazepam falsiﬁed prescriptions among all BZD falsiﬁed prescriptions increased. During the 2006 OPPIDUM survey, the analysis of the BZD modalities of use highlights clonazepam abuse liability (for example 23% of illegal acquisition), in second rank after ﬂunitrazepam. Studies based on data from the French health reimbursed system show that 1.5% of subjects with clonazepam dispensing had a deviant behaviour. Among BZD, clonazepam has the second most important doctor-shopping indicator (3%) after ﬂunitrazepam. All these data provide some arguments in favour of clonazepam abuse liability in real life and the necessity to reinforce its monitoring.
- Référence : Frauger et al., Fundamental & clinical pharmacology, 2011 Oct;25(5):633-41